UK Markets close in 6 hrs 42 mins
  • FTSE 100

    7,489.19
    +1.04 (+0.01%)
     
  • FTSE 250

    19,978.68
    +66.28 (+0.33%)
     
  • AIM

    912.71
    -2.04 (-0.22%)
     
  • GBP/EUR

    1.1836
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2097
    +0.0020 (+0.1681%)
     
  • BTC-GBP

    19,061.72
    -722.44 (-3.65%)
     
  • CMC Crypto 200

    535.87
    -21.48 (-3.85%)
     
  • S&P 500

    4,122.47
    -17.59 (-0.42%)
     
  • DOW

    32,774.41
    -58.09 (-0.18%)
     
  • CRUDE OIL

    90.22
    -0.28 (-0.31%)
     
  • GOLD FUTURES

    1,808.00
    -4.30 (-0.24%)
     
  • NIKKEI 225

    27,819.33
    -180.67 (-0.65%)
     
  • HANG SENG

    19,610.84
    -392.60 (-1.96%)
     
  • DAX

    13,566.16
    +31.19 (+0.23%)
     
  • CAC 40

    6,492.89
    +2.89 (+0.04%)
     

Spexis announces business update call to be held on July 28th

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Spexis AG / Key word(s): Conference
Spexis announces business update call to be held on July 28th
20.07.2022 / 07:30

Allschwil, Switzerland, July 20, 2022

Spexis announces business update call to be held on July 28th

  •  Conference call scheduled for Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET

Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET.

To participate, please use the following numbers:

France:  +33 (0)1 70 730 3 39
Germany:  +49 (0)69 22222 5197
Italy:   +39 0200638217
Switzerland:  +41 (0)44 580 7279
United Kingdom +44 (0)330 165 4012
United States  +1 646-828-8075

Please dial in approximately 10 minutes prior to the start of the call.  When asked, please provide the name of the event – “Spexis AG - Business and Strategy Update” – and the following confirmation code: 1507661.

The presentation will also be available via webcast:

A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section here or via the above link.

For further information, please contact:

For Investors: 
 
Hernan Levett
Chief Financial Officer
Spexis AG.
+41 61 567 16 00
IR@spexisbio.com
 
Raimund Gabriel
MC Services
spexis@mc-services.eu
Ph: +49 89 210 228 0

For Media:
 
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56
feldhaus@feldhaus-partner.ch
 
 
Dr. Brigitte Keller/Laurie Doyle
MC Services
spexis@mc-services.eu
Europe: +49 89 210 228 0
U.S.: +1 339 832 0752

 

 

About Spexis
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit: www.spexisbio.com.

Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.


End of Media Release

Language:

English

Company:

Spexis AG

Hegenheimermattweg 125

4123 Allschwil

Switzerland

Phone:

+41 61 567 1600

Fax:

+41 61 567 1601

E-mail:

info@spexisbio.com

Internet:

www.spexisbio.com

ISIN:

CH0106213793

Valor:

SPEX

Listed:

SIX Swiss Exchange

EQS News ID:

1401323


 

End of News

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting